You are here

Open

Reset

NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.


If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).

  1. RFA-ES-24-003: SBIR E-Learning for HAZMAT and Emergency Response (R43/R44 Clinical Trial Not Allowed)

    Release Date: 05-21-2024Open Date: 06-26-2024Due Date: 07-26-2024Close Date: 07-27-2024

    This SBIR NOFO focuses on the development of e-Learning health and safety training products from a variety of delivery methods to assist both students and instructors in the training and education process. Note that all products must be directly related to the health and safety training of workers exposed to hazardous materials (HAZMAT). Workers that may be exposed to these hazards include, but ar ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  2. RFA-DA-25-054: Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R43/R44 Clinical Trials Not Allowed)

    Release Date: 01-29-2024Open Date: 06-25-2024Due Date: 07-25-2024Close Date: 07-26-2024

    Background: Drug discovery and development is a high-cost, high-risk, and time-consuming endeavor where the failure rate of therapeutic candidates that enter clinical trials is 90%. Because of this, in recent years, artificial intelligence (AI), including machine learning ( ML) technologies, has been embraced to reduce clinical failure rates and to speed up drug discovery. AI/ML technologies are ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  3. RFA-DA-25-053: Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R41/R42 Clinical Trials Not Allowed)

    Release Date: 01-29-2024Open Date: 06-25-2024Due Date: 07-25-2024Close Date: 07-26-2024

    Background: Drug discovery and development is a high-cost, high-risk, and time-consuming endeavor where the failure rate of therapeutic candidates that enter clinical trials is 90%. Because of this, in recent years, artificial intelligence (AI), including machine learning (ML) technologies, has been embraced to reduce clinical failure rates and to speed up drug discovery. AI/ML technologies are u ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  4. OSD244-P002: Development of novel 5G Open RAN (Radio Access Networks) xApp and rApp Applications Open Topic

    Release Date: 10-03-2023Open Date: 05-15-2024Due Date: 03-31-2025Close Date: 07-08-2024

    OUSD (R&E) CRITICAL TECHNOLOGY AREA(S): FutureG; Sustainment & Logistics OBJECTIVE: The Department of Defense (DoD) is seeking the development and demonstration of xApps and/or rApps focused on security and security related network measurement. DoD anticipates increasing reliance on 5G and FutureG OpenRAN networks, and needs tools and techniques that will enhance the security and resilience of ...

    SBIRPhase I/Phase IIDepartment of DefenseOffice of the Secretary of Defense
US Flag An Official Website of the United States Government